Concord Biotech FY26 Financial Performance

Revenue: ₹1,054.9 crore (FY26) vs ₹1,200.1 crore (FY25)
PAT: ₹259.2 crore (FY26) vs ₹371.6 crore (FY25)

Reader Takeaway: Revenue and profit decline due to external factors; future growth hinges on new facilities and market recovery.

What just happened

Concord Biotech has reported a challenging fiscal year ending March 2026 (FY26). The company's consolidated revenue from operations fell by 12% to ₹1,054.9 crore, compared to ₹1,200.1 crore in the previous fiscal year (FY25). Profit After Tax (PAT) saw a more significant decline of 30%, dropping to ₹259.2 crore from ₹371.6 crore in FY25. The fourth quarter (Q4FY26) also reflected this trend, with revenue declining 24% year-on-year to ₹326.1 crore.

Why this matters

The decline in revenue and profitability indicates operational pressures that have directly impacted the company's financial performance. Investors will be closely watching how these headwinds are managed and if the company can return to its previous growth trajectory. The reduction in margins, with EBITDA margins falling from 42.2% to 34.8%, also raises concerns.

The backstory

Concord Biotech's FY26 performance was affected by several external factors. Management pointed to shifts in customer procurement strategies, moving from bulk to staggered quarterly orders, which impacted sales volumes. Regulatory delays, including those with CDSCO for EU supplies and US Veterans Affairs tender delays, also played a role. Geopolitical tensions and global trade uncertainties further slowed down procurement.

What changes now

The company is pushing ahead with growth initiatives despite the downturn. These include the commercialization of new manufacturing facilities for injectables and soft gels, establishment of a direct commercial footprint in the US via Stellon Biotech Inc., and entry into the Cell & Gene Therapy segment through an investment in Cellimune Biotech.

Risks to watch

Key risks for investors include the conversion of the company's order book, the timely resolution of regulatory hurdles impacting supplies to key markets like the EU, and the successful ramp-up of new manufacturing and business segments. The adjusted EBITDA margin, which stood at 38.8% excluding certain new facility and subsidiary expenses, highlights the potential for margin improvement if these new ventures stabilize.

Peer comparison

While specific peer results for FY26 are not detailed in the filing, Concord Biotech's performance indicates a challenging period for companies with significant export and tender-based businesses, likely affected by similar global and regulatory factors.

Context metrics (time-bound)

• FY26 Revenue: ₹1,054.9 crore (down 12% YoY)
• FY26 PAT: ₹259.2 crore (down 30% YoY)
• Q4FY26 Revenue: ₹326.1 crore (down 24% YoY)
• FY26 EBITDA Margin: 34.8% (down from 42.2% in FY25)

What to track next

Investors should monitor the company's ability to convert its existing order flow, the recovery of supply chains and procurement in affected markets, and the performance and profitability of its newly established injectables, soft gel, and Cell & Gene Therapy businesses in FY27. The stabilization of adjusted EBITDA margins will also be a key indicator.